Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma

Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma

In light of a global rise in the number of patients with type 2 diabetes mellitus (T2DM) and obesity, non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become t...

Full description

Bibliographic Details
Main Authors: Yumin Wang, Joshua S. Fleishman, Tongda Li, Yulin Li, Zhao Ren, Jichao Chen, Mingchao Ding
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
hepatocellular carcinoma
non-alcoholic fatty liver disease
metabolic dysfunction-associated steatotic liver disease
natural products
treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1336216/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1336216/full

Similar Items